Due to tumor heterogeneity, most believe that effective treatments should be tailored to the features of an individual tumor or tumor subclass. It is still unclear what information should be considered for optimal disease stratification, and most prior work focuses on tumor genomics. Here, we focus on the tumor micro-environment. Using a large-scale co-culture assay optimized to measure drug-induced cell death, we identify tumor-stroma interactions that modulate drug sensitivity. Our data show that the chemo-insensitivity typically associated with aggressive subtypes of breast cancer is not cell intrinsic, but rather a product of tumor-fibroblast interactions.
INTRODUCTION
associated with poor outcomes (Kalluri and Zeisberg, 2006) . Moreover, fibroblasts are well known 118 to supply growth factors and matrix proteins, which may alter how cells respond to DNA damage 119 (Lee et al., 2012) .
120
To identify interactions between tumor cells and stromal fibroblasts that alter drug response,
121
we used an in vitro co-culture system that was successfully used to study tumor-stroma interactions 122 in other contexts (Straussman et al., 2012) . In this experimental platform cancer cells are 123 genetically modified to express GFP, which facilitates rapid, quantitative, high-throughput, and 124 cancer cell specific measurement of drug response dynamics. We piloted this study using 125 TNBC cells, either grown in mono-culture or in co-culture with HADF, a primary non-immortalized 126 human fibroblast cell harvested from the adrenal gland. We determined α−smooth muscle actin
127
(SMA) expression, a marker of the "activated fibroblast" expression state, which is commonly 
136
(i.e. cytotoxicity) (Lee et al., 2012) . Total well fluorescence measured using a fluorescence plate 137 reader revealed that co-culture with HADF enhanced the proliferation rate of BT-20 cells to a small 138 extent. Furthermore, we found that co-culture with HADF potently blocked erlotinib-mediated 139 cytostasis of BT-20 cells, but had no effect on camptothecin sensitivity. Notably, well-based 140 fluorescence failed to capture the potent death that we observe by other methods following
141
camptothecin exposure, with all measurements in the time course recording higher values than the 142 initial pre-drug measurement (Supplemental Figure 3A and 1A). We were concerned that this 143 reflected a poor sensitivity of this assay, particularly with respect to quantifying the degree of 144 cytotoxicity rather than proliferation. Thus, 96 hours after drug exposure, we collected images of 145 these wells using fluorescence microscopy and quantified cell numbers from these images using a
146
CellProfiler-based automated analysis pipeline (Lamprecht et al., 2007) . Our quantitative image 147 analysis confirmed the growth rate increase induced by HADF, as well as the loss of erlotinib-
148
induced cytostasis in HADF co-culture (Supplemental Figure 3B) . Importantly, however, image 149 analysis revealed a strong stromal interaction that was not observed by well-based fluorescence 150 measurements. Less than 1% of BT-20 cells survived chronic camptothecin exposure if grown in 151 mono-culture, but roughly 25% of these cells survived in the presence of HADF (Supplemental 152 Figure 3C ). Taken together, these data indicate that well-based measurement of GFP fluorescence is appropriate for quantifying changes to proliferation, but not sufficient for quantifying the degree of 154 cell death in a population of cells.
9
Co-culture screen optimized to monitor cytotoxicity reveals widespread stromal influence on Because we were primarily focused on the study of cytotoxic DNA damaging agents, we apoptotic cell death (Figure 2A and B) (Montero et al., 2015) . At low concentrations, this dye exists 
174
To evaluate the role of stromal fibroblasts in DNA damage sensitivity, we selected six TNBC 175 cell lines (3 BL and 3 ML) that have relatively similar levels of sensitivity to DNA damage. These 176 JC-1 labeled TNBC cells were grown in mono-culture or in co-culture with each of a panel of 16 177 primary human fibroblasts. Each culture was exposed to increasing doses of 42 anticancer drugs
178
(at least one drug per class for all current FDA approved breast cancer drugs, Supplemental Tables found a strong overall correlation among biological replicates, indicating that the stromal influences observed were not due to measurement noise (Supplemental Figure 4) . To identify TNBC-fibroblast at early times (i.e. 8 hours), low doses (0.1 µM), and responses to anti-estrogen drugs
187
(Supplemental Table 4 ). Non-response to anti-estrogen compounds is expected as TNBCs do not 188 express estrogen or progesterone receptors.
189
The majority of TNBC cell-fibroblast interactions did not alter drug sensitivity (Supplemental 190 Figure 4A -B). Nonetheless, our screen revealed many striking phenotypes, which strongly altered 191 drug sensitivity in both positive and negative directions. To determine the reliability of these 192 measurements, we selected both strong and moderate phenotypes to validate by flow cytometry.
193
For example, our screen identified that palbociclib killed more than 80% of HCC-1143 cells, a 
201
WS1 (purple dots in Figure 2E ). This phenotype was interesting because our prior studies have
202
found that etoposide, a Topo II inhibitor, is minimally active in mono-culture, which was surprising
203
given the clinical utility of this compound (Lee et al., 2012) . Flow cytometry based analysis of cell 
209
Prior studies that have interrogated fibroblast-tumor cell-drug interactions have found that 210 these interactions generally result in drug resistance, with rare instances in which stromal cell 211 interactions lead to drug sensitization (Mcmillin et al., 2010; Straussman et al., 2012) . Mechanisms 212 that contribute to this directional variability have not been identified, likely because few drug 213 sensitizing phenotypes had been previously found. In contrast, our screen reveals that fibroblasts 214 sensitize and de-sensitize TNBC drug response with similar frequencies (Supplemental Figure 4B) . the observed directional variation. We sought to determine if certain TNBC cells, fibroblast cells, or 217 drugs were intrinsically more likely to be involved in sensitizing or de-sensitizing interactions
218
(Supplemental Figures 5-7) . Indeed, we found that some TNBC cells (e.g. MDA-MB-468), drugs
219
(e.g. sunitinib), or fibroblasts (e.g. WS1) appear to be involved in directionally biased interactions.
220
However, we wanted to integrate these insights to determine the relative importance of each of 221 these features in our dataset.
222
We performed principal component analysis (PCA) on our screening data. PCA uses the 223 correlation structure of the data to reduce data dimensionality to a smaller number of "principal 224 components" which maximally capture the variance of the dataset (Janes and Yaffe, 2006) . PCA
225
can be used to generate a simplified description of the observed data, and here, we were 226 particularly interested in using PCA to quantify the relative contribution of each measured influence
227
(e.g. specific tumor cells, fibroblasts, drugs, or unique combinations of each) to the overall observed 228 pattern of data.
229
PCA identified 10 principal components, with the first two components capturing 53% of the 
237
Another important insight derived from PCA of TNBCs grown in co-culture was that the 238 variation associated with BL vs. ML subtypes was captured exclusively on PC2, rather than PC1
239
( Figure 3C ). By definition, PC1 captures information that is unrelated to PC2, and in this dataset, 
264
whether fibroblast origin was associated with differences in the magnitude of drug response, we 265 generated maps using the percent viability in co-culture (i.e. y-axis data from Figure 2E ). From 266 these maps, differences between fibroblast lines were not apparent, suggesting that fibroblast origin 267 does not alter drug sensitivity magnitude (Supplemental Table 3 ). Next, to test if fibroblast origin 268 was associated with the degree to which drug responses were altered in co-culture, we generated 269 maps using the co-culture:mono-culture response ratio ( Figure 4B and Supplemental Figure 9 ).
270
From this analysis, a clear difference between fibroblast lines was visible, with fibroblasts derived 271 from common sites of metastasis generally enhancing survival of TNBCs, whereas those derived 272 from other organs generally were neutral or enhanced TNBC cell death. Interestingly, these 273 patterns were observed across nearly all drugs, revealing that the location specific trends were 274 more robust than drug specific responses. To determine if these visual trends were statistically 275 robust, we calculated the mean response ratio for each unique cancer-fibroblast-drug combination,
276
and separated these data by metastatic location ( Figure 4C ). These data confirmed a statistically 277 significant difference in the directionality of influence between fibroblasts derived from organs that 278 are common or uncommon metastatic sites. Additionally, we also performed statistical analyses 279 including only the 5039 drug responses, which were the largest and most significantly changed 280 phenotypes (Supplemental Figure 4D ). This analysis of extreme "outliers" revealed that, while the 281 total number of "hits" were similar between metastatic and non-metastatic sites, the directionality of 282 these hits was significantly different between these groups, and consistent with the insights generated using average response ratio ( Figure 4D ). Taken together, these results are consistent 
306
A second mechanism by which fibroblast cells could enhance drug efficacy could be by 307 metabolizing the drugs, creating a more potent or more bioavailable compound ( Figure 5A , example 308 ii). This mechanism was recently reported to explain a microbiome-drug interaction that modulates 309 toxicity of the chemotherapeutic 5-FU (García-González et al., 2017) . To test the role of fibroblast-310 mediated drug metabolism, we focused on drugs that activate death through induction of DNA damage. For this set of compounds, drug potency should be proportional to level of γ−H2AX, which 312 marks sites of DNA double stranded breaks. We quantified γ−H2AX nuclear intensity in the 313 presence and absence of fibroblast co-culture. These measurements were made at 4 time points 314 following exposure to teniposide, a Topo II inhibitor similar to doxorubicin, which is used clinically in 315 the treatment of TNBC (doxorubicin fluorescence limits use of this compound). We used GFP-
316
labeled TNBC cells to identify TNBC cell nuclei and images were quantified using automated image 317 analysis (CellProfiler, (Lamprecht et al., 2007) ). Overall, we found many cases where fibroblasts 318 modulated γ−H2AX levels ( Figure 5D ). Importantly, however, the degree to which γ−H2AX was 319 modulated by fibroblast cells was poorly correlated with the phenotypic influence of these 320 fibroblasts ( Figure 5D ). Furthermore, we inspected the most strongly sensitizing and de-sensitizing 
326
The insights gained from γ−H2AX intensity are also consistent with our general observation 327 that fibroblast cells influence drug sensitivity in similar ways across diverse classes of drugs. In 328 other words, it does not appear that the mechanisms by which fibroblast cells influence the drug 329 responses in TNBC cells are specific to the drug compounds themselves or drug-specific responses 330 of TNBC cells. Drug-induced cell death is the product of at least two independent influences: the 331 drug-specific cell response (i.e. the ability of a drug to change a cell from a healthy to a dead state) 332 and the degree to which the cell is "primed" for death (i.e. how "close" the healthy cell is to dying) 333 (Chonghaile et al., 2011; Montero et al., 2015) . Thus, a third mechanism that we tested was 334 whether fibroblasts alter the degree of mitochondrial apoptotic priming. We used the BH3 profiling mitochondria. We selected five fibroblast cells that produced the strongest and most consistent 338 modulation of drug sensitivity. The mitochondrial response to BIM peptide was quantified by 339 monitoring cytochrome c retention by flow cytometry ( Figure 5F ). BH3 profiling revealed that 340 fibroblast co-culture conditions significantly altered the mitochondrial priming state of BT-20 and
341
MDA-MB-231 cells. Furthermore, the degree to which mitochondrial priming was increased or 342 decreased was also highly correlated with relative drug sensitivity observed in our co-culture screen 343 ( Figure 5G ).
345
Fibroblast-secreted IL8 induces hyper-sensitivity to DNA damaging chemotherapy 346 WS1 (skin), C12385 (uterine), and HUF (uterine) cells, sensitized all six TNBC cell lines to 347 nearly every drug tested. We prioritized understanding mechanisms by which these cells induce 348 broad-spectrum drug sensitization, as these may be therapeutically relevant insights. To begin, we 349 determined whether conditioned media from these fibroblast cells also induced drug sensitization.
350
Conditioned media was collected following 48 hours of culture with fibroblasts and added to TNBC 351 cells prior to addition of teniposide. To measure the rate of TNBC cell death, we used Sytox green, 352 a cell impermeant dye that is fluorescent only when bound to DNA. We found that conditioned 353 media from WS1, HUF, and C12385 sensitized all six TNBC cell lines tested to teniposide ( Figure   354 6A). In contrast, conditioned media from Hs27A, a bone fibroblast cell, generally did not alter TNBC 355 drug response, although these data were more variable across TNBC cells.
356
To identify secreted factors that are responsible for these phenotypes, we profiled 357 conditioned media for the presence of 45 common cytokine, chemokine, and growth factors ( Figure   358 6B). We reasoned that the relative secretion profile for factors that induce drug sensitization should 359 be inversely correlated with the relative drug sensitivity observed in our co-culture screen. Of the 45 360 cytokines profiled, we observed strong negative correlation only for IL8 (Figure 6C and D) . sensitivity and secretion of IL6, a cytokine that is already known to induce resistance to DNA whereas recombinant IL6 decreased the rate of cell death by approximately 2-fold ( Figure 6E ). To 367 further determine the role of IL8 secretion in the drug sensitization phenotype observed in 368 conditioned media, we tested IL8 neutralizing antibodies with conditioned media from WS1, HUF, or 369 C12385 fibroblasts. In all three cases, IL8 neutralizing antibodies significantly inhibited the drug 370 sensitization induced by conditioned media ( Figure 6F ). Notably, IL8 neutralizing antibodies failed to 371 restore drug sensitivity to the levels observed in the absence of fibroblast conditioned media,
372
suggesting that other secreted factors also contribute to the drug sensitization phenotype.
374

DISCUSSION
375
In this study, we explored interactions between tumor cells and stromal cells to identify 376 those that modulate sensitivity to commonly used chemotherapeutics. We found that fibroblasts can 377 alter drug sensitivity of tumor cells, and that the responses were highly variable, both in magnitude 378 and in direction. Our statistical analysis clarified that the directional variability in fibroblast influence 379 is predominantly associated with the anatomical organ from which the fibroblast cells were 
465
Cell viability assays were performed either using CellTiter-Glo (cat# G7570), for cells grown in 466 mono-culture, or flow cytometry, for co-culture assays (other than the co-culture screen, described 
476
in DMEM and allowed to adhere overnight. Drugs were added from a 1000x stock and cells were 477 exposed for the specified times. Cells were trypsinized at the specified times, suspended in PBS at 
483
Growth rate measurements using GFP labeled cells
484
To determine cell proliferation rate using a fluorescence plate reader, TNBC cells were stably 485 transfected with GFP (pRetroQ-AcGFP1-N1). Transfected cells were selected with puromycin (BT-486 20 at 1.5µg/mL, 468 at 0.5 µg/mL and 231 at 2 µg/mL). Cells were selected until a parallel non-487 transformed plate exposed to puromycin was completely dead. The selected population was built functions (FisherTest, t test, etc.) . PCA was performed using SIMCA and data were z scored 554 (mean centered and unit variance scaled). Hierarchical clustering was performed using Spotfire 555 using the default settings (UPGMA clustering method; Euclidean distance measure; Average value 556 ordering weight; z-score calculation normalization method; empty value replacement: NA). Analysis 557 of flow cytometry data was performed using FloJo.
559
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